Qyuns Therapeutics Co., Ltd. announced that on April 24, 2024, it has entered into an exclusive outlicensing agreement with Hansoh (Shanghai) Healthtech Co., Ltd. regarding the research and development, manufacturing, and commercialization of QX004N, a monoclonal antibody inhibitor targeting IL-23p19, within mainland China, Taiwan, the Special Administrative Region of Hong Kong and the Special Administrative Region of Macau (the "Greater China") (the "License-Out Agreement"). The Company retains all its rights to QX004N outside Greater China, where it can continue to pursue development as a monotherapy or as part of its combination strategy for this drug. The board of directors of the Company is of the opinion that the collaboration will strengthen the Company's business layout in the field of autoimmune diseases and is in line with the Company's long-term strategic objective of maximizing the value of its pipeline.